ABSCIENCES (EPA:AB) | WebDisclosure

Basculer en Français

9784	Companies
196006	Keywords
127065	Articles
104238	Press releases

Home
Companies
ABSCIENCES

PRESS RELEASE

published on 10/16/2025 at 20:57, 3 months 17 days ago

AB Science provides intitial Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia
AB Science provides initial Phase 1 data for combination of AB8939 with Venetoclax for refractory or relapsed Acute Myeloid Leukemia. Promising results incl. 100% disease control rate and 100% response rate

AB Science AB8939 Phase 1 Data AML Venetoclax
PRESS RELEASE

published on 10/16/2025 at 20:57, 3 months 17 days ago

AB Science présente les premières données de phase 1 de la combinaison d’AB8939 et du venetoclax dans le traitement de la leucémie myéloïde aiguë réfractaire ou en rechute
AB Science présente les premières données de phase 1 de la combinaison d’AB8939 et du venetoclax dans le traitement de la leucémie myéloïde aiguë réfractaire ou en rechute. Des résultats prometteurs pour les patients atteints de LMA

Traitement AB Science AB8939 Leucémie Myéloïde Aiguë Venetoclax
BRIEF

published on 10/14/2025 at 08:41, 3 months 19 days ago

AB Science Reports Promising Initial Data from AML Study

Clinical Trial AML Treatment AB Science AB8939 Venetoclax
BRIEF

published on 10/14/2025 at 08:41, 3 months 19 days ago

AB Science publie des données initiales prometteuses issues d'une étude sur la LAM

Essai Clinique AB Science AB8939 Traitement De La LAM Venetoclax
PRESS RELEASE

published on 10/14/2025 at 08:36, 3 months 19 days ago

AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939
AB Science releases positive initial data on combination treatment of AB8939 with Venetoclax for refractory or relapsed Acute Myeloid Leukemia (AML), showing promising results in patients with unfavorable genetic profiles. Virtual conference scheduled with renowned experts in AML

Virtual Conference AB Science AB8939 AML Venetoclax
PRESS RELEASE

published on 10/14/2025 at 08:36, 3 months 19 days ago

AB Science tiendra une conférence virtuelle le jeudi 16 octobre 2025, de 14 h à 15 h CET, afin de faire le point sur l'étude de phase 1 avec AB8939
AB Science publie les premières données de la combinaison de AB8939 avec Vénétoclax dans le traitement de la LMA, avec des résultats très encourageants. Une conférence virtuelle est prévue le 16 octobre 2025

Conférence Virtuelle AB Science AB8939 Venetoclax LMA
PRESS RELEASE

published on 10/10/2025 at 18:17, 3 months 23 days ago

Rapport financier semestriel 2025
BRIEF

published on 08/04/2025 at 08:03, 5 months 29 days ago

AB Science Completes EUR 2.55 Million Private Placement

Private Placement Shareholders Clinical Development AB Science EUR 2.55 Million
BRIEF

published on 08/04/2025 at 08:03, 5 months 29 days ago

AB Science finalise un placement privé de 2,55 millions d'euros

Actionnaires Placement Privé Développement Clinique AB Science 2,55 Millions D'euros
PRESS RELEASE

published on 08/04/2025 at 07:58, 5 months 29 days ago

AB Science announces the successful completion of a 2.55 million euros private placement
AB Science successfully completes EUR 2.55 million private placement to fund clinical development. New shares issued with warrants attached

Private Placement Shareholders Clinical Development AB Science EUR 2.55 Million

Accesswire

Published on 02/02/2026 at 23:55, 2 hours 30 minutes ago

2026 Tunkillia Development Drilling Programs Begin
Published on 02/02/2026 at 23:55, 2 hours 30 minutes ago

55 North Mining Announces Winter Exploration Drill Program at Last Hope Gold Project
Published on 02/02/2026 at 23:25, 3 hours ago

Western Announces Sale of GlassMasters Investment
Published on 02/02/2026 at 22:05, 4 hours 20 minutes ago

Organto Foods to Attend Fruit Logistica 2026 in Berlin, Germany From February 4-6, 2026
Published on 02/02/2026 at 15:00, 11 hours 25 minutes ago

Jericho Energy Ventures Strategically Terminates SmartKem LOI to Advance Independent Data Center Energy Infrastructure Platform

View all ACCESSWIRE

EQS Group

Published on 02/02/2026 at 20:00, 6 hours 25 minutes ago

CGTN AMERICA & CCTV UN: Cultural Event Celebrating the Spring Festival and the 55th Anniversary of China-U.S. Ping-Pong Diplomacy
Published on 02/02/2026 at 19:57, 6 hours 28 minutes ago

US federal court grants preliminary injunction allowing Sunrise Wind construction to resume
Published on 02/02/2026 at 19:42, 6 hours 43 minutes ago

EQS-Adhoc: ProSiebenSat.1 publishes preliminary figures for financial year 2025
Published on 02/02/2026 at 19:05, 7 hours 20 minutes ago

Virtual Science AI launches the life science industry's first medical congress AI solution for real-time event conversational intelligence
Published on 02/02/2026 at 19:00, 7 hours 25 minutes ago

PATRIMOINE ET COMMERCE: INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL AU TITRE DE L’ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AMF

Les Echos

Published on 02/02/2026 at 18:23, 8 hours 2 minutes ago

Monthly disclosure of the total number of shares and voting rights - January 2026
Published on 02/02/2026 at 18:23, 8 hours 2 minutes ago

TF1 - Déclaration mensuelle des actions et droits de vote - Janvier 2026
Published on 02/02/2026 at 18:00, 8 hours 25 minutes ago

Covivio - Information on total number of voting rights and share capital
Published on 02/02/2026 at 18:00, 8 hours 25 minutes ago

Covivio Hotels - Informations relatives au nombre total de droits de vote et d’actions composant le capital social
Published on 02/02/2026 at 18:00, 8 hours 25 minutes ago

Covivio - Informations relatives au nombre total de droits de vote et d’actions composant le capital social

View all LES ECHOS COMFI WIRE